Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 768

7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 748

A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 742

A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea

9:00AM-11:00AM: Abstract Number: 777

a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 752

Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus

9:00AM-11:00AM: Abstract Number: 790

Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study

9:00AM-11:00AM: Abstract Number: 764

Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 780

Belimumab Use in African-American Patients in an U.S. Academic Medical Center

9:00AM-11:00AM: Abstract Number: 774

BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 782

Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review

9:00AM-11:00AM: Abstract Number: 745

Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 751

Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 786

Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 794

Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)

9:00AM-11:00AM: Abstract Number: 746

Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 784

Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE

9:00AM-11:00AM: Abstract Number: 772

Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 760

Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE

9:00AM-11:00AM: Abstract Number: 796

Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards

9:00AM-11:00AM: Abstract Number: 776

Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique

9:00AM-11:00AM: Abstract Number: 749

Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 775

Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina

9:00AM-11:00AM: Abstract Number: 761

Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 779

Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 744

Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 759

Gene Signature for Glucocorticoid, from in Vitro to In Vivo

9:00AM-11:00AM: Abstract Number: 765

High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings

9:00AM-11:00AM: Abstract Number: 755

Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 767

Hydroxychloroquine Induced Retinopathy in SLE

9:00AM-11:00AM: Abstract Number: 741

Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients

9:00AM-11:00AM: Abstract Number: 737

Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy

9:00AM-11:00AM: Abstract Number: 770

Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus

9:00AM-11:00AM: Abstract Number: 743

Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 795

Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?

9:00AM-11:00AM: Abstract Number: 757

Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)

9:00AM-11:00AM: Abstract Number: 793

Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity

9:00AM-11:00AM: Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 740

Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment

9:00AM-11:00AM: Abstract Number: 756

Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients

9:00AM-11:00AM: Abstract Number: 762

Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins

9:00AM-11:00AM: Abstract Number: 750

Predictors of Corticosteroid Use in the Systemic Lupus International Collaborating Clinics Inception Cohort – a Multivariate Analysis

9:00AM-11:00AM: Abstract Number: 738

Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 771

Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE

9:00AM-11:00AM: Abstract Number: 797

Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations

9:00AM-11:00AM: Abstract Number: 758

Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 769

Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort

9:00AM-11:00AM: Abstract Number: 783

Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE

9:00AM-11:00AM: Abstract Number: 773

Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 763

Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 739

Safety and Efficacy of Rituximab in the Treatment of Refractory Systemic Lupus Erythematosus: Results from a National Register

9:00AM-11:00AM: Abstract Number: 792

Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE

9:00AM-11:00AM: Abstract Number: 754

The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 791

The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact

9:00AM-11:00AM: Abstract Number: 747

The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study

9:00AM-11:00AM: Abstract Number: 781

The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness

9:00AM-11:00AM: Abstract Number: 788

Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels

9:00AM-11:00AM: Abstract Number: 789

Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development

9:00AM-11:00AM: Abstract Number: 787

Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 753

Vitamin D Improves Systolic Blood Pressure in SLE

9:00AM-11:00AM: Abstract Number: 785

What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 766

Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].